Objectives/Hypothesis: Information on polymorphous low-grade adenocarcinoma (PLGA) consists primarily of case reports and small institutional series with varying recurrence rates. In this report, we describe our institutional experience and conduct a review of the literature to assess the overall incidence of PLGA among oral salivary gland tumors and determine recurrence rates.
INTRODUCTION
In 1984, Evans and Batsakis characterized a previously unrecognized subset of minor salivary gland adenocarcinoma 1 and termed this cytologically bland tumor polymorphous low-grade adenocarcinoma (PLGA) because of the histological diversity that was observed.
Previous to the clinicopathologic description of PLGA, this tumor had been nonuniformly referred to as lowgrade papillary adenocarcinoma, terminal duct carcinoma, and lobular carcinoma. [2] [3] [4] The World Health Organization recognized the diagnosis in 1990, 5 and some series report PLGA to be one of the most common malignant salivary gland tumors. 6, 7 Although the diagnosis is based on histological characteristics of PLGA, attempts have been made to identify immunohistochemical markers to help distinguish PLGA from other salivary gland tumors, specifically adenoid cystic carcinoma. We refer interested readers to the review by Darling et al. for comprehensive discussion. 8 Briefly, no standard immunohistochemical markers are in routine use, with most diagnoses made based on the hematoxylin and eosin morphology. Smooth muscle actin (SMA) is expected to be expressed in adenoid cystic carcinoma, but not in PLGA, and vimentin, glial fibrillary acidic protein, c-Kit, and other markers may have diagnostic utility. [9] [10] [11] [12] It is important to distinguish PLGA from high-grade tumors (e.g., adenoid cystic carcinoma) because PLGA tends to have lower local recurrence rates and have lower metastatic potential. 13 Although PLGA is considered to behave in a low-grade fashion, PLGA has been documented to spread distantly to the lungs and liver. 14, 15 reported to occur more than 10 years after initial treatment. 16 Although PLGAs represent a significant proportion of intraoral salivary gland malignancies, large series primarily describe pathology, and most case series contain 10 to 20 patients at a single institution. In this report, we present our institutional experience and report a review of the literature to better understand overall prevalence, and to determine recurrence rates of PLGA of the head and neck.
MATERIALS AND METHODS

Case Series
Approval for this study was obtained from the University of North Carolina (UNC) Biomedical Institutional Review Board. Patients were identified in the UNC Pathology Database who had a pathologic diagnosis of PLGA from January 1, 1990 to January 1, 2010. All slides were reexamined by a single pathologist (W.K.F.) and assessed for growth pattern, papillary architecture, perineural invasion, vascular invasion, and margin status.
The length of patient follow-up, documented recurrences, and last known disease status were also obtained for each patient. Data were tabulated using Excel 2008 (Microsoft Corp., Redmond, WA), and statistical analysis was performed using GraphPad Prism version 5 for Macintosh (GraphPad Software, San Diego, CA).
Review of the Literature
PubMed and MEDLINE databases were queried for "polymorphous low-grade adenocarcinoma" and "polymorphous low grade adenocarcinoma" from January 1984 to January 2012. A total of 258 English-language articles were identified. Two independent reviewers (A.J.K., C.M.W.) reviewed abstracts and excluded 124 studies that were not on PLGA, did not present new data (review, editorials, and commentaries), focused on histology without presenting new cases, tested new diagnostic methods, or focused on expression or mutational analysis of tumors. Of the included articles, subgroups of case reports (n 5 1), case series (n 3) and large series (n > 3) were generated ( Fig. 1) .
RESULTS
Patient Characteristics
In our institutional series, 20 patients were identified who had PLGA tumors verified by a pathologist. The average age at presentation was 53 years, with a range of 32 to 85 years. The cohort had a female predominance (1:1.5). The most common initial presentation was an asymptomatic mass (45%). The average follow-up period was 47 months. The palate was the most common initial site for the tumor (60%); however, in our series, 45% of patients presented with extrapalatal tumors including the retromolar trigone, gingiva, nasal septum, and maxillary sinus (Table I) .
Histology
Diagnosis was made based on pathological features. PLGA tumors are composed of uniform, cytologically bland cells that vary from epitheliod, cuboidal, columnar, to spindled; they grow in solid, glandular, cribriform, trabecular, cystic, fascicular, or papillary arrangements (Fig. 2) . Their nuclei are ovoid with pale chromatin; nucleoli are inconspicuous and mitotic figures are infrequent. Stroma varies from hyaline to mucoid to fibrovascular; the tumor is nonencapsulated, and typically infiltrates into adjacent stroma. Of the 20 tumors in our institutional series, 13 demonstrated multiple growth patterns (Table I) , 11 tumors demonstrated tubular growth patterns, nine tumors demonstrated solid growth patterns, seven tumors had cribriform growth patterns, and one tumor demonstrated both papillary and angiomatoid growth patterns. In the series, we did not identify a correlation between histological patterns and recurrence rates.
Treatment and Outcomes
In our institutional series, 18 patients were treated primarily by wide, local, surgical excision, one patient was treated with primary radiation therapy, and one patient received primary neutron beam therapy. Average follow-up time was 2 years (range, 5 months to 13 years). Three patients had recurrence, and one patient had persistent disease. One patient died due to lung metastases 2.5 years after diagnosis.
Review of the Literature
In the literature search, we identified eight studies that documented the incidence of intraoral salivary gland tumors, specifically pleomorphic adenoma (PA), mucoepidermoid (ME), adenoid cystic carcinoma (ACC), adenocarcinoma (AC), and PLGA ( Figs. 1 and 3) . 6, 7, [17] [18] [19] [20] [21] [22] In these eight studies, the mean incidence of PLGA was 5.3% (range, 0.0% to 15.7%). Combining data of the eight studies resulted in a total of 8,423 intraoral salivary gland tumors, and the overall incidence was determined: PA (46.4%), ME (11.46%), ACC (10.2%), AC (2.4%), and PLGA (1.2%) (Fig. 4) . Other benign (8.7%) and malignant (5.0%) salivary tumors included but are not limited to sialadenoma papilliferum, myoepithelioma, basal cell adenoma, oncocytoma, canalicular adenoma, sialadenoma, salivary duct carcinoma, myoepithelial carcinoma, and carcinoma ex pleomorphic adenoma, and acinic cell carcinoma. Excluding the large series by Tian et al., 20 a total of 628 tumors were identified, 5.3% of which were diagnosed as PLGA.
Overall, the literature search resulted in 54 case reports, eight case series (n 3), and 17 PLGA series (Fig. 1) . The case reports (n 5 1) and case series (n 3) that included patient follow-up were pooled to produce a cohort of cases that included 72 patients (see Supporting Information, Table 1 , in the online version of this article). The age range in the cohort of cases was 12 to 84 years old, with an average presenting age of 54 years. The gender distribution was nearly equal between male (49%) and female (51%). Although the palate was the most common site of presentation in the case cohort with 25 cases (35%), additional sites were identified including the lips, nasal cavity, mandible, lacrimal gland, maxillary sinus, and floor of mouth (Fig. 5 ) (see Supporting Information, Table 2 , in the online version of this article).
Seventeen series identified a total of 384 patients diagnosed with PLGA who had follow-up and recurrence data (see Supporting Information, Table 3 , in the online version of this article). The average age of presentation was 57 years, with a slight female predominance (53%). Recurrence rates varied dramatically between studies, from 0% in three studies [23] [24] [25] to 33.3% in three studies. 13, 26, 27 Of the 384 patients, there were 70 reported recurrences resulting in an overall recurrence rate of 18.2% (see Supporting Information, Table  3 , in the online version of this article). The average time to recurrence in this group was 70 months (range, between 5 and 288 months). The recurrence rate in the 72 patient cohort of cases was 23.6%, which was not statistically different from the recurrence rate of the 384-patient series (P 5.33). The overall recurrence rate in the 456 identified cases was 19.1%. Of reports that detailed patient-specific data in regard to latency between initial diagnosis and recurrence, 50% of recurrences occurred by 35 months (Fig. 6A) . The longest latency between treatment and recurrence was found to be 24 years. 16 Of the recurrences, 54% were local, 32% were nodal, and 8% were distant. The overall recurrence rate with of palatal tumors and pooled samples of all other sites was similar, 23.5% and 27.7%, respectively (P 5.59, Fig. 6B ). Eleven tumors with recurrence data were reported to have originated in major salivary glands. The rate of recurrence of tumors presenting in parotid, submandibular, or sublingual glands was 36.4% and was not statistically significant (P 5.41) compared to the recurrence rates at all other sites of 24.2%. Distant metastasis were identified in the lungs and the liver. 15, 28, 29 The primary treatment modality was surgical resection of the tumor; however, 2.1% of patients received primary radiation therapy, and 33.1% received adjuvant radiation therapy after surgical resection. Rates of recurrence for surgical excision without adjuvant radiation was 24.4% compared to 26.1% for surgical excision with adjuvant radiation therapy (P 5.83).
DISCUSSION
Because PLGA and adenoid cystic carcinoma have different prognoses with respect to risk of local recurrence, distant metastasis, and death due to the neoplasm, it is important to distinguish these two neoplasms. This can be difficult if sampling is limited to core or incisional biopsy of a large lesion. Both can show similar architectural patterns (e.g., cribriform architecture). Fortunately, most adenoid cystic carcinomas show admixture of the cribriform pattern with tubular or solid patterns, regularly show extracellular gray matrix in pseudolumina, and routinely show a more basaloid cytology in the ductal component. SMA immunoreactivity is In a total of 8,423 pooled intraoral salivary gland tumor cases, the overall incidence of PA, other benign tumors, ME, ACC, AC, PLGA, and other malignant tumors was 46.4%, 18.8%, 11.46%, 10.2%, 2.4%, 1.2%, and 9.4%, respectively. AC 5 adenocarcinoma; ACC 5 adenoid cystic carcinoma; ME 5 mucoepidermoid; PA 5 pleomorphic adenoma; PLGA 5 polymorphous low-grade adenocarcinoma.
expected in the majority of adenoid cystic carcinoma but in a minority of PLGA. Both neoplasms need to be resected with negative margins, such that a diagnostic error on the initial biopsy should be recognized at the time of diagnosis of the resection specimen.
The prevalence of PLGA among oral salivary gland tumors varies greatly by series from 0% to 15.7%. 6, 21 In a pooled sample of over 8,000 intraoral salivary gland tumors identified in the literature, the reported incidence of PLGA was 1.2%; however, this number was significantly influenced by the low incidence of PLGA in the series that identified 31 PLGA tumors out of 6,982 oral salivary gland tumors (0.44%). 20 This low rate of PLGA tumors observed by Tian and colleagues may represent a difference in geographic or racial rates of PLGA in an Eastern Chinese population or could also result from under diagnosis.
PLGA is classically a neoplasm of the minor salivary glands that most commonly presents with involvement of the palate; however, cases have been documented throughout the oral cavity and in the sublingual gland, submandibular gland, and parotid gland.
In the published case reports, 24% of tumors were identified in major salivary glands (i.e., parotid, submandibular, or sublingual gland). Primary tumors have also been reported in locations outside of the head and neck including the vagina and breast. 15, 30 Although surgical excision is the mainstay of treatment, in our institutional series, two patients elected to undergo primary radiation because of the magnitude of surgical excision required at presentation. A third patient in our institutional series underwent adjuvant radiation therapy because of positive margins (Table I ). In the literature review, one-third of patients underwent adjuvant radiation therapy. Although we are unable to ascertain the reason in all cases, close and positive margins were frequently denoted. The recurrence rate with adjuvant radiation was not significantly different than with excision alone.
Polymorphous low-grade adenocarcinoma is a lowgrade and indolent neoplasm, with 10% to 20% risk of local recurrence and a low risk for distant metastasis and death. In the review of the literature the recurrence rates ranged from 0% to 33% with an average recurrence rate in nearly 500 tumors of 19.1%. Although 50% of tumors recurred by 35 months, PLGA has the ability to recur decades after the initial treatment, with one recurrence documented 24 years after initial treatment. In our study, there was no difference in recurrence rates from the palate or major salivary glands compared to a pooled subset of all other tumors. The high rates of recurrence and the long latency between initial diagnosis and recurrence make it essential that the clinician remain vigilant for decades after the tumor is initially treated.
CONCLUSION
PLGA has a recurrence rate that approaches 20%; therefore, although histologically low grade, this tumor does have a significant potential for recurrence and even regional and distant metastasis. Wide surgical resection is the mainstay of PLGA treatment, and the role of radiation is unclear. It is essential to maintain long-term follow-up, as local recurrence or metastasis can occur several years later. Recurrence by site. Location of the initial tumor does not significantly affect the rate of recurrence. Recurrence rate of the palatal tumor was 23.5% compared to 27.4% in a pooled sample of all other sites (P 5.59). n.s. 5 not significant. 
